Contact Us
Drug Search Results
More Filters [+]

Afuresertib

Alternative Names: afuresertib, gsk2110183, gsk-21110183, gsk 21110183, GSK21110183, GSK 21110183, GSK-21110183
Latest Update: 2024-11-20
Latest Update Note: News Article

Product Description

Afuresertib is a reversible, ATP-competitive, oral, low-nanomolar, pan-AKT kinase inhibitor. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229853/)

Mechanisms of Action: Akt Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Afuresertib

Countries in Clinic: China, Korea, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Breast Cancer

Phase 2: Adenocarcinoma|Cervical Cancer|Endometrial Cancer|Esophageal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Ovarian Cancer|Prostate Cancer|Small Cell Lung Cancer

Phase 1: Fallopian Tube Cancer|Healthy Volunteers|Peritoneal Cancer|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
LAE205INT3101

P3

Recruiting

Breast Cancer

2026-10-30

LAE202CN2101

P2

Active, not recruiting

Esophageal Cancer|Small Cell Lung Cancer|Gastrointestinal Cancer|Cervical Cancer|Endometrial Cancer|Adenocarcinoma|Non-Small-Cell Lung Cancer

2024-06-25

LAE201INT2101

P2

Completed

Prostate Cancer

2023-12-27

LAE203CN2101

P1

Completed

Triple Negative Breast Cancer

2023-12-11

Recent News Events

Date

Type

Title

11/20/2024

News Article

 Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

06/05/2024

PubMed

 Identification of hub genes and potential therapeutic mechanisms related to HPV positive head and neck squamous carcinoma based on full transcriptomic detection and ceRNA network construction.

05/23/2024

News Article

 Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer

04/29/2024

News Article

 Laekna Releases 2023 ESG Report

02/18/2024

PubMed

 Bulk and single-cell sequencing identified a prognostic model based on the macrophage and lipid metabolism related signatures for osteosarcoma patients.

01/04/2024

News Article

 Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

12/28/2023

PubMed

 Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions